ANTl-5T4 ANTIGEN BINDING DOMAINS, ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
AssigneeSalubris Biotherapeutics, Inc.
InventorsSamuel L. MURPHY, Jonathan P. MCNALLY, Binyam Z. BEZABEH, John LI
Life of this patent
Estimating the term…
Loading patent…
AssigneeSalubris Biotherapeutics, Inc.
InventorsSamuel L. MURPHY, Jonathan P. MCNALLY, Binyam Z. BEZABEH, John LI
Estimating the term…
The disclosure provides anti-5T4 antigen binding domains, which can be incorporated into antibodies and receptors, including bispecific anti-5T4 antibodies, biparatopic anti-5T4 antibodies, and antibody-drug conjugates of same comprising a first antigen binding domain that specifically binds to a first 5T4 epitope, a second antibody antigen binding domain that specifically binds to a second 5T4 epitope that is not the same as the first 5T4 epitope, wherein the first antigen binding domain is operably linked to the second antigen binding domain, and a chemotherapeutic agent. The disclosure further provides methods of using same for the treatment of cancer.
An antibody-drug conjugate, comprising:
(canceled)
-8. (canceled)
-12. (canceled)
-16. (canceled)
(canceled)
-24. (canceled)
(canceled)
-33. (canceled)
-49. (canceled)
A nucleic acid system encoding the bispecific antibody comprising:
(canceled)
-57. (canceled)
A method of treating cancer in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody-drug conjugate, wherein the antibody-drug conjugate comprises:
-68. (canceled)
An antigen binding domain comprising a heavy chain variable region domain and a light chain variable region domain;
-85. (canceled)
Dependencies are inferred from the claim text.